Centre Hospitalier Universitaire De Dijon
- Address
- 14 Rue Paul Gaffarel, 21000 Dijon, France
Oncology and Hematologic Malignancies
At Centre Hospitalier Universitaire De Dijon, a major share of research focuses on neoplasms and related blood cancers. Trials are studying diseases such as melanoma, lymphoma, breast cancer, lung cancer, biliary tract cancer, and bladder cancer, with the goal of improving treatment effectiveness, reducing recurrence, and refining post-surgical care.
- Melanoma, including resected and advanced forms
- Classical Hodgkin lymphoma and marginal zone lymphoma
- Advanced biliary tract, colon, anal, and bladder cancers
- Studies testing new immunotherapy and combination treatment strategies
These studies reflect a strong interest in better cancer control, especially for patients with advanced or high-risk disease.
Cardiovascular and Thrombotic Disease Research
The site also conducts important work in cardiovascular diseases and blood clotting disorders. Research includes acute coronary syndrome, atrial fibrillation, stroke, venous thromboembolism, and broader atherosclerotic risk, with trials aimed at preventing major events and improving long-term protection.
- Stroke prevention after ischemic events or transient ischemic attack
- Atrial fibrillation and clot prevention
- Atherosclerotic cardiovascular risk and lipid-related disease
- Balancing anticoagulation benefits with bleeding risk
Much of this research is designed to help clinicians choose safer and more effective ways to prevent heart attacks, strokes, and clot-related complications.
Respiratory and Critical Care Studies
Research in respiratory tract diseases and intensive care is another clear strength at this hospital. Trials cover COVID-19, community-acquired pneumonia, ventilator-associated pneumonia, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and other progressive lung conditions, often focusing on treatment benefit in hospital settings.
- COVID-19 treatment strategies in hospitalized patients
- Severe bacterial pneumonia and ventilator-associated pneumonia
- Progressive interstitial lung disease and pulmonary fibrosis
- Therapies intended to improve recovery and survival
This area combines infection management with chronic lung disease care, reflecting a broad respiratory research portfolio.
Dermatology, Immune-Mediated, and Inflammatory Conditions
Clinical trials at the Dijon site also address skin and connective tissue diseases and immune system diseases. Key conditions include atopic dermatitis, psoriasis, hidradenitis suppurativa, prurigo nodularis, polymyalgia rheumatica, and Sjögren’s syndrome, with studies aimed at symptom control and better long-term disease management.
- Chronic inflammatory skin diseases such as atopic dermatitis and psoriasis
- Hidradenitis suppurativa and prurigo nodularis
- Autoimmune and inflammatory disorders including polymyalgia rheumatica and Sjögren’s syndrome
- Testing new therapies and treatment-sparing approaches
This research supports improved quality of life for patients living with persistent inflammatory conditions.
Eye Disease and Imaging Innovation
The department’s strong radiology and diagnostic imaging profile is reflected in trials on eye diseases and advanced imaging tools. Studies include glaucoma, macular edema, and imaging contrast evaluation, with the aim of preserving vision and improving diagnostic performance.
- Glaucoma and visual field preservation
- Macular edema linked to retinal vein occlusion
- Evaluation of new MRI contrast agents
- Research focused on better diagnosis and monitoring
These trials combine clinical eye care with imaging research, showing how the site links diagnosis and treatment innovation.
Digestive, Metabolic, and Surgical Oncology Research
Another active area involves digestive system diseases and nutritional and metabolic disorders. Trials cover ulcerative colitis, hypertriglyceridemia, colon carcinoma, and biliary tract carcinoma, often aiming to improve disease control, reduce relapse, or support better post-treatment outcomes.
- Inflammatory bowel disease, especially ulcerative colitis
- High triglycerides and related cardiovascular risk
- Colon and biliary tract cancers after surgery or chemotherapy
- Studies evaluating maintenance treatment and recurrence prevention
These projects highlight a mix of cancer, digestive, and metabolic research with practical implications for everyday care.
Neurology, Pregnancy, and Other Clinical Research Areas
Beyond its main specialties, the site contributes to trials in pathological conditions and broader clinical research, including intracerebral hemorrhage, preeclampsia, and pulmonary embolism. Some studies also involve healthy volunteers or imaging-related questions, supporting a wide-ranging research environment.
- Brain bleeding and stroke-related outcomes
- Pregnancy complications such as preeclampsia
- Pulmonary embolism and anticoagulation decisions
- Supportive research in imaging, prevention, and clinical surveillance
These trials show the breadth of clinical investigation at the Centre Hospitalier Universitaire De Dijon, extending well beyond one disease area.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 27 therapeutic areas and 15 of 617 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 562 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 99 by active trials.
lock +98 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +70 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Dijon
lock Showing 1 of 478 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 617 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 37 | Unknown | 2014-03-24 | 2026-06-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
